Advertisement

Methylprednisolone Acetate Injection

[17 June 2016]

Products Affected - Description

Methylprednisolone acetate injection, Sandoz
40 mg/mL, 1 mL vials, 1 count (NDC 00781-3131-71)
40 mg/mL, 1 mL vials, 10 count (NDC 00781-3131-95)
40 mg/mL, 10 mL vials, 1 count (NDC 00781-3136-70)
80 mg/mL, 1 mL vials, 1 count (NDC 00781-3132-71)
80 mg/mL, 1 mL vials, 10 count (NDC 00781-3132-95)
80 mg/mL, 5 mL vials, 1 count (NDC 00781-3137-75)
 
Methylprednisolone acetate injection, Teva
40 mg/mL, 1 mL vials, 1 count (NDC 00703-0031-01)
40 mg/mL, 1 mL vials, 25 count (NDC 00703-0031-04)
40 mg/mL, 5 mL vials, 1 count (NDC 00703-0043-01)
40 mg/mL, 10 mL vials, 1 count (NDC 00703-0045-01)
80 mg/mL, 1 mL vials, 1 count (NDC 00703-0051-01)
80 mg/mL, 1 mL vials, 25 count (NDC 00703-0051-04)
80 mg/mL, 5 mL vials, 1 count (NDC 00703-0063-01)

Reason for the Shortage

  • Sandoz and Teva could not provide a reason for the shortage.
  • Pfizer had Depo-Medrol injection on a short-term shortage due to increased demand for Solu-Medrol.

Available Products

Depo-Medrol injection, Pfizer
20 mg/mL, 5 mL vials, 1 count (NDC 00009-0274-01)
40 mg/mL, 1 mL vial, 1 count (NDC 00009-3073-01)
40 mg/mL, 1 mL vial, 25 count (NDC 00009-3073-03)
40 mg/mL, 5 mL vials, 1 count (NDC 00009-0280-02)
40 mg/mL, 5 mL vials, 25 count (NDC 00009-0280-51)
40 mg/mL, 10 mL vials, 1 count (NDC 00009-0280-03)
40 mg/mL, 10 mL vials, 25 count (NDC 00009-0280-52)
80 mg/mL, 1 mL vials, 1 count (NDC 00009-3475-01)
80 mg/mL, 1 mL vial, 25 count (NDC 00009-3475-03)
80 mg/mL 5 mL vials, 1 count (NDC 00009-0306-02)
80 mg/mL 5 mL vials, 25 count (NDC 00009-0306-12)

Estimated Resupply Dates

  • Sandoz has methylprednisolone acetate injection temporarily unavailable and the company cannot estimate a release date.
  • Teva has all methylprednisolone acetate presentations on back order and the company estimates a release date of November 2016.

Implications for Patient Care

  • FDA closed New England Compounding Company in Massachusetts due to a fungal meningitis outbreak linked to methylprednisolone acetate injections compounded by this pharmacy.
  • All commercially available products contain a preservative such as myristyl gamma picolinium chloride or benzyl alcohol.
  • Methylprednisolone acetate is not approved for epidural administration and contraindicated for intrathecal use.

Related Shortages

Updated

June 17 and 13, May 27, 16 and 10, March 2, 2016; December 15, September 25, August 12 and 4, June 15, April 30 and 7, March 20 and 4, February 2, January 9, 2015; December 12, October 10, September 22 and 5, August 28 and 13, July 31 and 15, June 30 and 19, April 24, March 17 and 11, February 3, January 15, 2014; November 14, September 26, August 22 and 6, July 23 and 16, May 3, April 19, March 15, January 22, 2013; November 20, September 26, August 21, July 26 and 9, June 20, May 22, 2012, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing